AACR 2024: Brenus Pharma Unveils Promising and Robust Pre-clinical Efficacy Extrapolating Human Conditions with STC-1010

Contributed by: Business Wire

Logo

Tags

Research

Clinical Trials

Biometrics

Other Health

Biotechnology

Pharmaceutical

Health

Science

Oncology

Other Science

AACR 2024

More Like This

George Alzeeb, PhD, Innovation Manager at Brenus Pharma, presenting the company’s latest preclinical data on STC-1010 — an off-the-shelf vaccine-based immunotherapy — during the Late-Breaking session at the American Association for Cancer Research (AACR) Annual Meeting 2025. This poster highlights the potential of STC-1010 to induce a robust anti-tumor response, supporting Brenus Pharma’s novel approach in immuno-oncology and clincial development.

AACR 2025: Brenus Pharma Presents Late-breaking Preclinical Data on its “off-the-shelf” Next-generation Vaccine-based Immunotherapy Candidate, STC-1010, Now Moving to Clinic

ASCO 2024: Brenus Pharma Presented “BreAK-CRC” First-in-human (FIH) Phase I/IIA Trial of STC-1010: a Next-generation Cancer Vaccine Targeting mCRC

Brenus Pharma, Winner of the Call for Proposals "Innovations in Biotherapies and Bioproduction for France 2030", Receives €5 Million for Its Anticancer Vaccine Immunotherapy

Brenus Pharma Publishes Promising Proof of Concept Results of their Therapeutic Platform in the Scientific Frontiers in Oncology Journal. (1)

Brenus Pharma Joins the Paris Saclay Cancer Cluster (PSCC) to Collaborate at the Heart of Innovation in Oncology

Brenus Pharma graduates from the Creative Destruction Lab’s 2023/2024 Global Cancer Stream, in partnership with North American Universities.

SMC Laboratories Reveals Innovative STAM™-HCC/IO+ Mouse for Identifying and Developing Novel Therapeutic Drugs for Liver Cancer, Blazing a Trail in the Immuno-Oncology Field

How Cutting-Edge Immunotherapies Are Redefining Cancer Treatment Options